GB202104609D0 - New Treatments for Pain - Google Patents

New Treatments for Pain

Info

Publication number
GB202104609D0
GB202104609D0 GBGB2104609.9A GB202104609A GB202104609D0 GB 202104609 D0 GB202104609 D0 GB 202104609D0 GB 202104609 A GB202104609 A GB 202104609A GB 202104609 D0 GB202104609 D0 GB 202104609D0
Authority
GB
United Kingdom
Prior art keywords
pain
new treatments
treatments
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2104609.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sevenless Therapeutics Ltd
Original Assignee
Sevenless Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sevenless Therapeutics Ltd filed Critical Sevenless Therapeutics Ltd
Priority to GBGB2104609.9A priority Critical patent/GB202104609D0/en
Publication of GB202104609D0 publication Critical patent/GB202104609D0/en
Priority to EP22718975.0A priority patent/EP4313151A1/en
Priority to AU2022250712A priority patent/AU2022250712A1/en
Priority to CA3213593A priority patent/CA3213593A1/en
Priority to JP2023559696A priority patent/JP2024512979A/en
Priority to PCT/EP2022/058337 priority patent/WO2022207673A1/en
Ceased legal-status Critical Current

Links

GBGB2104609.9A 2021-03-31 2021-03-31 New Treatments for Pain Ceased GB202104609D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB2104609.9A GB202104609D0 (en) 2021-03-31 2021-03-31 New Treatments for Pain
EP22718975.0A EP4313151A1 (en) 2021-03-31 2022-03-29 Sos1 inhibitors and ras inhibitors for use in the treatment of pain
AU2022250712A AU2022250712A1 (en) 2021-03-31 2022-03-29 Sos1 inhibitors and ras inhibitors for use in the treatment of pain
CA3213593A CA3213593A1 (en) 2021-03-31 2022-03-29 Sos1 inhibitors and ras inhibitors for use in the treatment of pain
JP2023559696A JP2024512979A (en) 2021-03-31 2022-03-29 New treatment for pain
PCT/EP2022/058337 WO2022207673A1 (en) 2021-03-31 2022-03-29 Sos1 inhibitors and ras inhibitors for use in the treatment of pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2104609.9A GB202104609D0 (en) 2021-03-31 2021-03-31 New Treatments for Pain

Publications (1)

Publication Number Publication Date
GB202104609D0 true GB202104609D0 (en) 2021-05-12

Family

ID=75783634

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2104609.9A Ceased GB202104609D0 (en) 2021-03-31 2021-03-31 New Treatments for Pain

Country Status (1)

Country Link
GB (1) GB202104609D0 (en)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011172A1 (en) 1990-01-23 1991-08-08 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1994002518A1 (en) 1992-07-27 1994-02-03 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1998055148A1 (en) 1997-06-05 1998-12-10 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising cyclodextrins
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
WO2018068017A1 (en) 2016-10-07 2018-04-12 Araxes Pharma Llc Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018115380A1 (en) 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019122129A1 (en) 2017-12-21 2019-06-27 Boehringer Ingelheim International Gmbh Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2020173935A1 (en) 2019-02-26 2020-09-03 Boehringer Ingelheim International Gmbh New isoindolinone substituted indoles and derivatives as ras inhibitors
WO2020173938A1 (en) 2019-02-27 2020-09-03 Becton Dickinson France Valve stopper for a medical injection device and medical injection device for injecting at least one composition
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011172A1 (en) 1990-01-23 1991-08-08 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1994002518A1 (en) 1992-07-27 1994-02-03 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
WO1998055148A1 (en) 1997-06-05 1998-12-10 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising cyclodextrins
WO2018068017A1 (en) 2016-10-07 2018-04-12 Araxes Pharma Llc Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018115380A1 (en) 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019122129A1 (en) 2017-12-21 2019-06-27 Boehringer Ingelheim International Gmbh Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2020173935A1 (en) 2019-02-26 2020-09-03 Boehringer Ingelheim International Gmbh New isoindolinone substituted indoles and derivatives as ras inhibitors
WO2020173938A1 (en) 2019-02-27 2020-09-03 Becton Dickinson France Valve stopper for a medical injection device and medical injection device for injecting at least one composition
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
"uniprot", Database accession no. P01116-2
ACS MED CHEM LETT, vol. 9, no. 9, 2018, pages 941 - 946
CANCER DISCOVERY, 19 August 2020 (2020-08-19)
FINNINMORGAN, J PHARM SCI, vol. 88, no. 10, October 1999 (1999-10-01), pages 955 - 958
FRY, METHODS MOL BIOL, vol. 462, 2009, pages 345 - 62
H. LIEBERMANL. LACHMAN: "Pharmaceutical Dosage Forms: Tablets", vol. 1, 1980, MARCEL DEKKER
HILLIG ET AL., PNAS, vol. 116, no. 7, 12 February 2019 (2019-02-12), pages 2551 - 2560
J MED CHEM, vol. 61, no. 19, 2018, pages 8875 - 8894
J. B. FELLJ. P. FISCHERB. R. BAERJ. F. BLAKEK. BOUHANAD. M. BRIEREK. D. BROWNL. E. BURGESSA. C. BURNSM. R. BURKARD, J. MED. CHEM., 2020
J. CANONK. REXA. Y. SAIKIC. MOHRK. COOKED. BAGALK. GAIDAT. HOLTC. G. KNUTSONN. KOPPADA, NATURE, vol. 575, 2019, pages 217 - 223
J. HALLINL. D. ENGSTROML. HARGISA. CALINISANR. ARANDAD. M. BRIEREN. SUDHAKARV. BOWCUTB. R. BAERJ. A. BALLARD, CANCER DISCOVERY, vol. 10, 2020, pages 54 - 71
J. M. OSTREMU. PETERSM. L. SOSJ. A. WELLSK. M. SHOKAT, NATURE, vol. 503, 2013, pages 548 - 551
KESSLER ET AL., PROC NATL ACAD SCI USA., vol. 116, no. 32, 6 August 2019 (2019-08-06), pages 15823 - 15829
LIANGCHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, no. 6, 2001, pages 981 - 986
LU ET AL., CHEMMEDCHEM, vol. 11, 2016, pages 814 - 821
M. P. PATRICELLIM. R. JANESL. S. LIR. HANSENU. PETERSL. V. KESSLERY. CHENJ. M. KUCHARSKIJ. FENGT. ELY, CANCER DISCOVERY, vol. 6, 2016, pages 316 - 329
M. R. JANESJ. ZHANGL. S. LIR. HANSENU. PETERSX. GUOY. CHENA. BABBARS. J. FIRDAUSL. DARJANIA, CELL, vol. 172, 2018, pages 578 - 589.e517
PNAS, vol. 116, no. 7, 2019, pages 2551 - 2560
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 116, no. 7, 2019, pages 2551 - 2560
RSC MED. CHEM., vol. 11, 2020, pages 760
SASAGAWA ET AL., NATURE CELL BIOLOGY, vol. 7, no. 4, April 2005 (2005-04-01), pages 365 - 373
VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, vol. 25, no. 2, 2001, pages 1 - 14
WANG ET AL., CURR CHEM GENOMICS, vol. 1, 2008, pages 27 - 33

Similar Documents

Publication Publication Date Title
GB202108224D0 (en) Treatment
GB202016058D0 (en) Therapeautic treatment
GB202104609D0 (en) New Treatments for Pain
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202316077D0 (en) New treatments for pain
GB202309744D0 (en) New treatments for pain
GB202214722D0 (en) New treatments for pain
GB202214652D0 (en) New treatments for pain
GB202314527D0 (en) New treatment for pain
GB202108300D0 (en) New treatment
GB202108302D0 (en) New treatment
GB202016955D0 (en) Therapeutic treatments
GB202009086D0 (en) New treatments
GB202006236D0 (en) New treatment
GB202006659D0 (en) Therapeutic treatments
EP4098263A4 (en) Treatment for chondrodystrophia
GB202114373D0 (en) Treatment
GB202109815D0 (en) Treatment
GB202109812D0 (en) Treatment
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202103122D0 (en) Treatment
GB202102488D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)